Compare SOPA & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOPA | QUCY |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Singapore | Germany |
| Employees | N/A | 13 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 5.9M |
| IPO Year | 2021 | 2021 |
| Metric | SOPA | QUCY |
|---|---|---|
| Price | $0.42 | $0.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 336.2K |
| Earning Date | 05-19-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,171,635.00 | N/A |
| Revenue This Year | $2.43 | $74.34 |
| Revenue Next Year | $71.20 | $171.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 45.00 | N/A |
| 52 Week Low | $0.32 | $0.40 |
| 52 Week High | $6.28 | $0.74 |
| Indicator | SOPA | QUCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 43.42 |
| Support Level | $0.34 | $0.43 |
| Resistance Level | $0.69 | $0.53 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 32.36 | 25.20 |
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.